S-1/A: Alpha Cognition Files Amendment for Share Resale Amidst FDA Review of Alzheimer's Drug

Alpha Cognition Inc. files an amendment to its registration statement for the resale of common shares by selling stockholders, as it awaits FDA review of its Alzheimer's drug, ALPHA-1062.

Summary

• Alpha Cognition Inc., a biopharmaceutical company, has filed an amendment to its Form S-1 registration statement related to the resale of up to 42,676,511 common shares by selling stockholders.
• These shares were previously issued in private placements between August 2023 and January 2024.
• The company will not receive any proceeds from the sale of these shares.
• Alpha Cognition is currently focused on the FDA review of its New Drug Application (NDA) for ALPHA-1062, an oral tablet formulation for mild-to-moderate Alzheimer's disease, with a PDUFA goal date of July 27, 2024.
• The company is also pursuing the out-licensing of its TBI indication to Alpha Seven Therapeutics.
• Alpha Cognition is an emerging growth company and a smaller reporting company, allowing it to comply with reduced public company reporting requirements.
• The company's common shares are traded on the CSE under the symbol ACOG and on the OTCQB under the symbol ACOGF.
• Recent developments include filing a new composition-of-matter patent for ALPHA-1062, completing a private placement, and the FDA accepting the NDA for ALPHA-1062.
• The company faces risks related to its financial position, business development, industry competition, commercialization, intellectual property, government regulation, and employee matters.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive developments such as the FDA review and patent filing, the company's financial situation and dependence on future capital raises create significant uncertainty.

Positives

• FDA acceptance of the NDA for ALPHA-1062 with a PDUFA goal date of July 27, 2024.
• Filing of a new composition-of-matter patent for ALPHA-1062, potentially extending protection to 2044.
• Completion of a private placement, raising gross proceeds of $8.45 million.
• Plans to out-license the TBI indication of ALPHA-1062 to Alpha Seven Therapeutics, allowing for focused development in that area.

Negatives

• The company has incurred significant net losses and expects to continue to incur significant expenses and operating losses for the foreseeable future.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company will need substantial additional capital to meet its financial obligations and pursue its business objectives.
• The company's business is heavily dependent on the successful development, regulatory approval, and commercialization of ALPHA-1062.
• The company faces significant competition in an environment of rapid technological and scientific change.

Risks

• The company's ability to generate revenue and achieve profitability depends significantly on the FDA review of its filed NDA, continued development and commercialization of its product candidates, if approved.
• The company may encounter substantial delays in its preclinical studies and clinical trials or may not be able to conduct or complete its preclinical studies or clinical trials on the timelines it expects, if at all.
• Use of the company's therapeutic candidates could be associated with side effects, adverse events or other properties or safety risks, which could delay or preclude approval, cause the company to suspend or discontinue clinical trials, abandon a therapeutic candidate, limit the commercial profile of an approved label or result in other significant negative consequences that could severely harm the company's business, prospects, operating results and financial condition.
• The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable.
• Even if the company obtains regulatory approval for a product candidate, its products will remain subject to regulatory scrutiny.
• The company's stock price may be volatile, and you may not be able to resell common shares at or above the price you paid.

Future Outlook

The company plans to continue its development and commercialization activities for ALPHA-1062 in mild-to-moderate Alzheimer's disease, including commercial manufacturing, and pursue the out-licensing of its TBI indication to Alpha Seven.

Management Comments

• The company does not expect ALPHA-1062 to be commercially available immediately following approval.
• The Company will need to raise substantial additional capital in order to fund its operations and commercialization plans for ALPHA-1062, should the product be approved.

Industry Context

The document highlights the challenges in Alzheimer's drug development, noting the limited success in the field and the high failure rate of clinical studies. It also acknowledges the competitive landscape with numerous companies pursuing treatments for Alzheimer's and traumatic brain injury.

Comparison to Industry Standards

• The document mentions Biogen's Aduhelm and Corium's Adlarity as recent FDA approvals in the Alzheimer's space, highlighting the limited success in drug development for this disease.
• It notes that over 500 clinical studies have been completed since 2003, with only Aduhelm and Adlarity receiving FDA approval, compared to a success rate of 50% to 80% for all other drug candidates.
• The document also mentions companies such as Biogen, Eli Lilly, Corium, Taurz, Vasopharm, Neuren Pharmaceuticals, Abliva, and AB Science as competitors developing therapeutics for similar indications.
• In the Traumatic Brain Injury market, the document mentions Vasopharm, SanBio/Sumitomo, Ostuka/Avanir Pharmaceuticals, Biogen, and Cellvation as companies currently in clinical trials.

Related Party Transactions

• The Company entered into a loan agreement with Alpha Seven Therapeutics, Inc., (Alpha Seven) a related party through a common director and officers of the Company, to advance an amount up to $150,000.
• The Company has entered into contracts with regulatory consultants to provide advice and assist in preparing documentation for regulatory submissions to the FDA.

Stakeholder Impact

• Shareholders: Potential dilution from future equity offerings.
• Employees: Job security dependent on the company's financial stability and success of ALPHA-1062.
• Patients: Potential access to a new treatment option for Alzheimer's disease.
• Suppliers: Continued business relationship dependent on the company's financial health.

Next Steps

• Respond to regulatory questions and inquiries from FDA in a satisfactory manner and negotiate the commercial label and approval of the product with FDA, which is anticipated in Q3 2024.
• Continue its development activities and commercialization preparations around ALPHA-1062.
• Complete the out-license the TBI asset into Alpha Seven where Alpha Seven plans to raise the additional capital to advance the TBI program.

Key Dates

Keywords

ALPHA-1062, Alzheimer's disease, NDA, FDA, Clinical trials, Biopharmaceutical, Drug development, Private placement, Out-licensing, Neurodegenerative diseases, ACOG, ACOGF